Literature DB >> 20836759

Versatile applications of microRNA in anti-cancer drug discovery: from therapeutics to biomarkers.

Haruhisa Iguchi1, Nobuyoshi Kosaka, Takahiro Ochiya.   

Abstract

Over the past several years, microRNAs (miRNAs) have been identified as a fine-tuner in a wide array of biological processes, including development, cell growth and metabolism. Recent studies have shown that many kinds of miRNAs act as oncomirs or tumor suppressors in tumors where the miRNA genes are up- or down- regulated, respectively. These dysregulations occur through a variety of mechanisms, such as genetic alterations, epigenetic repression or altered expression of transcription factors which target miRNAs. The aberrant expressions of miRNAs are observed not only in tumor lesions but also in plasma and serum of cancer patients. These characteristics of miRNAs have created extensive interest in tapping into them for diagnosis and prognosis as well as drug discovery in cancer therapy. In this literature, the significance of miRNAs in tumor initiation and development is first reviewed. Second topic is extracellular miRNAs as biomarkers for cancer classification and prediction. Further, we focus on secretory machinery of miRNAs and share new evidence suggesting that extracellular miRNAs can play biological roles beyond mere biomarkers. Extending this concept, our hypothetical model that extracellular miRNAs may function as a signaling molecule in a crosstalk between cancer cells and their surrounding cells is presented. Finally, we discuss the potential of miRNAs for therapeutic applications in clinical oncology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20836759     DOI: 10.2174/157016310793180648

Source DB:  PubMed          Journal:  Curr Drug Discov Technol        ISSN: 1570-1638


  12 in total

1.  Phospho-ΔNp63α/microRNA network modulates epigenetic regulatory enzymes in squamous cell carcinomas.

Authors:  Edward A Ratovitski
Journal:  Cell Cycle       Date:  2014-01-06       Impact factor: 4.534

Review 2.  Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review.

Authors:  Peter Csermely; Tamás Korcsmáros; Huba J M Kiss; Gábor London; Ruth Nussinov
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

3.  miR-493 induction during carcinogenesis blocks metastatic settlement of colon cancer cells in liver.

Authors:  Koji Okamoto; Tatsuya Ishiguro; Yutaka Midorikawa; Hirokazu Ohata; Masashi Izumiya; Naoto Tsuchiya; Ai Sato; Hiroaki Sakai; Hitoshi Nakagama
Journal:  EMBO J       Date:  2012-02-28       Impact factor: 11.598

Review 4.  miR-210: fine-tuning the hypoxic response.

Authors:  Mircea Ivan; Xin Huang
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

Review 5.  Circulating microRNAs in cancer: origin, function and application.

Authors:  Ruimin Ma; Tao Jiang; Xixiong Kang
Journal:  J Exp Clin Cancer Res       Date:  2012-04-30

6.  Genome-wide small RNA sequencing and gene expression analysis reveals a microRNA profile of cancer susceptibility in ATM-deficient human mammary epithelial cells.

Authors:  Jill E Hesse; Liwen Liu; Cynthia L Innes; Yuxia Cui; Stela S Palii; Richard S Paules
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

7.  Modeling of miRNA and drug action in the EGFR signaling pathway.

Authors:  Jian Li; Vikash Pandey; Thomas Kessler; Hans Lehrach; Christoph Wierling
Journal:  PLoS One       Date:  2012-01-11       Impact factor: 3.240

8.  Identification of miRNAs contributing to neuroblastoma chemoresistance.

Authors:  Duncan Ayers; Pieter Mestdagh; Tom Van Maerken; Jo Vandesompele
Journal:  Comput Struct Biotechnol J       Date:  2015-04-29       Impact factor: 7.271

9.  Tumor Protein p63/microRNA Network in Epithelial Cancer Cells.

Authors:  Edward A Ratovitski
Journal:  Curr Genomics       Date:  2013-11       Impact factor: 2.236

10.  miRNome traits analysis on endothelial lineage cells discloses biomarker potential circulating microRNAs which affect progenitor activities.

Authors:  Ting-Yu Chang; Tse-Shun Huang; Hsei-Wei Wang; Shing-Jyh Chang; Hung-Hao Lo; Ya-Lin Chiu; Yen-Li Wang; Chung-Der Hsiao; Chin-Han Tsai; Chia-Hao Chan; Ren-In You; Chun-Hsien Wu; Tsung-Neng Tsai; Shu-Meng Cheng; Cheng-Chung Cheng
Journal:  BMC Genomics       Date:  2014-09-18       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.